Docoh
Loading...

APOP Cellect Biotechnology

Filed: 9 Nov 20, 8:12am

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

November 2020 (No. 2)

Commission File Number 

001-37846

 

CELLECT BIOTECHNOLOGY LTD.

(Translation of registrant’s name into English)

 

23 Hata’as Street

Kfar Saba, Israel 44425

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F        Form 40-F 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): 

 

 

 

 

 

 

On November 8, 2020 Cellect Biotechnology Ltd. (the “Company”) reconvened its annual general meeting of shareholders at which the Company’s ordinary shareholders and ADS holders passed all agenda items as proposed, as described further in Exhibit 99.1 to the Company’s Form 6-K furnished by the Company to the Securities and Exchange Commission on October 20, 2020.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 Cellect Biotechnology Ltd.
   
 By:/s/ Eyal Leibovitz
  Name: Eyal Leibovitz
 Date: November 9, 2020 Title:   Chief Financial Officer

 

 

2